AMRN
Amarin
Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline’s Lovaza.
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 1.56B; Volume: 1.85M; AvgVol 3m: 8.38M; Beta: 2.81;
Cost estimate:
P/E: –; EPS: -0.04; EPS growth quarter/prev quarter: 300.90%;
EPS growth this year: 83.10%; EPS growth past 5 years: 27.30%;
EPS ttm: -0.04;
P/S: 3.35; P/B: 3.21; P/Cashflow: 3.33; P/FCF: 110.24;
Sales: 546.00M; Sales growth quarter/prev quarter: 34.20%; Sales growth past 5 years: 51.30%;
Profitability:
Gross Margin: 78.10%; Profit Margin: -2.30%; Operating Margin: -3.50%;
ROA – return on assets: -1.40%; ROE – return on equity: -2.20%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.04;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.90%; Insider Transactions:0.00%;
Institutional Ownership: 44.50%; Institutional Transactions: -4.53%;
Data update: 07.10.2020.